In this paper we review an approach to estimating the causal effect of a timevarying treatment on time to some event of interest. This approach is designed for the situation where the treatment may have been repeatedly adapted to patient characteristics, which themselves may also be time-dependent. In this situation the effect of the treatment cannot simply be estimated by conditioning on the patient characteristics, as these may themselves be indicators of the treatment effect. This so-called time-dependent confounding is typical in observational studies. We discuss a new class of failure time models, structural nested failure time models, which can be used to estimate the causal effect of a time-varying treatment, and present methods for estimating and testing the parameters of these models.
Introduction
This paper offers a new approach to estimating, from observational data, the causal effect of a time-dependent treatment on time to an event of interest in the presence of timedependent confounding variables. This approach is based on a new class of failure time models, the structural nested failure time models (SNFTM). The primary goal of this paper is to motivate the need for structural nested failure time models. To achieve this goal in the most straightforward manner, we shall assume that the event times are observed without censoring, and that there is no missing or misclassified data. Additional complications that arise when these assumptions are not satisfied are discussed in Robins et al. (1992) and Robins (1993) .
The approach using SNTFMs will be useful in any observational study in which there exist time-dependent risk factors that are also predictive for subsequent exposure to the treatment under study, i.e. in any study where there are time-dependent covariates that correlate with the final outcome of the treatment, but also with the amount or type of treatment over time. This situation arises in any observational study in which there is "treatment by indication", i.e. the treatment is not predetermined by the investigator, but adapted to the current condition of the patient. The problem then is to distinguish between treatment effect and selection bias (i.e. confounding). For example, in an observational study for the effect of AZT treatment on HIV-infected subjects, subjects with low CD4 lymphocyte counts at a given time are subsequently at increased risk of developing AIDS and are for that reason more likely to be treated with AZT. Thus the covariate variables "low CD4-count" is a risk factor for AIDS, but is also a predictor of subsequent treatment with AZT. The problem is then to isolate the effect of AZT treatment as given according to a predetermined plan (which may take into account covariates) from the confounding effect of CD4-count. As a second example, many physicians withdraw women from exogenous estrogens at the time they develop an elevated blood cholesterol, since both exogenous estrogens and elevated blood cholesterol are considered possible cardiac risk factors. Therefore, in a study of the effect of postmenopausal estrogen on cardiac mortality, the covariate variables "cholesterol level" is a predictor of subsequent exposure to estrogens, but also correlates with the outcome "cardiac mortality". As a third example, in observational studies of the efficacy of cervical cancer screening on mortality, women who have had operative removal of their cervix due to invasive disease are no longer at risk for further screening (i.e. exposure), but are at increased risk for death. Therefore, the covariate, "operative removal of the cervix", is an independent risk factor for death, but also a predictor of subsequent exposure. As a final epidemiologic example, in occupational mortality studies, unhealthy workers who terminate employment early are at increased risk of death compared to other workers and receive no further exposure to the chemical agent under study. Therefore, the time-dependent covariate "employment status" is an independent risk factor for death, and a predictor of exposure to the study agent.
Epidemiologists refer to the covariates in the preceding examples as "time-dependent confounders". It may be important to analyze the data from any of the above studies using the approach presented in this paper.
For pedagogic purposes, we shall illustrate our models and assumptions throughout the paper by the problem of estimating, from data obtained in an observational study, the effect of treatment with the drug AZT on time to clinical AIDS in asymptomatic subjects with newly diagnosed human immunodeficiency virus (HIV) infection. We shall suppose that measurements on current AZT dosage as well as on various time-dependent covariates, such as weight, temperature, hematocrit, and CD4-lymphocyte count, are recorded at regularly spaced time points, until the development of clinical AIDS. These time points, which we denote by 0 = τ 0 < τ 1 < τ 2 < · · · < · · · < τ K , may for instance correspond to clinic visits at which the measurements are obtained, with time defined as time since the diagnosis of HIV infection.
Our goal will be to identify and estimate, for each treatment regime, the time-to-AIDS distribution that would have been observed if (typically counter to fact) each study subject had followed the AZT treatment history prescribed by the regime. We shall call each such distribution an AZT treatment regime-specific, counterfactual, time-to-AIDS distribution.
The treatment regimes we study need not be static. A treatment regime is a rule that assigns to each possible covariate history through time τ k , an AZT dosage rate a k to be taken in the interval (τ k , τ k+1 ]. A simple example of a treatment regime is "take an AZT dosage a k of 1, 000 milligrams of AZT daily in the interval (τ k , τ k+1 ] if the hematocrit measured at τ k exceeds 30; otherwise take no AZT in the interval".
Our interest in AZT treatment regime-specific, counterfactual time-to-AIDS distributions is based on the following considerations. Suppose, after the completion of the study, a further individual with newly diagnosed HIV infection, whom we shall call "the infected subject", wishes to use the data from the completed study to select the AZT dosage schedule that will maximize his expected or median number of years of AIDS-free survival. If the "infected subject" is considered exchangeable with the subjects in the trial, then he would wish to follow the AZT treatment regime whose regime-specific, counterfactual time-to-AIDS distribution has the largest expected or median value.
In Section 3 we show that the AZT treatment regime-specific, counterfactual time-to-AIDS distributions are identified from the observed data under the assumption that the investigator has succeeded in recording sufficient data on the history of all covariates to ensure that, at each time τ k , given the covariate history and the AZT treatment history up till τ k , the AZT dosage rate in (τ k , τ k+1 ] is independent of the regime-specific, counterfactual time-to-AIDS. Robins (1992) refers to this assumption as the assumption of no unmeasured confounding factors. In other words, under this assumption at each time point the treatment can be viewed as depending only on recorded information up till that point and external factors that are not predictive of (counterfactual) survival.
In Section 4 we introduce structural nested failure time models (SNFTM). An SNFTM models the magnitude of the causal effect of a (final) blip of AZT treatment in the interval (τ k , τ k+1 ] on time-to-AIDS, as a function of past AZT and covariate history. We show that, under the assumption of no unmeasured confounding, the null hypothesis of no causal effect of AZT on time-to-AIDS is equivalent to the null hypothesis that the parameter vector of any SNFTM is 0.
The term "structural" in SNFTM derives terminology used in the social science and econometric literature (e.g. Rubin (1978) ). Our models are "structural", because they directly model regime-specific, counterfactual time-to-AIDS distributions. In Sections 6 and 7 we discuss two different methods to fit SNFTMs and to use them for inference.
In Section 6 we show that, under the assumption of no unmeasured confounding, SNFTMs can be understood as a component of a particular reparameterization of the joint distribution of the observables. We use this reparameterization to develop likelihoodbased tests of the causal null hypothesis of no effect of AZT-exposure on time-to-AIDS. We also show how to estimate the AZT-treatment regime-specific, counterfactual timeto-AIDS distributions, in the case that the null hypothesis of no causal effect of AZT on time-to-AIDS is rejected.
In Section 7 we present an alternative, semiparametric approach to test the null hypothesis of no treatment effect and to estimate the parameters in an SNFTM. This approach, G-estimation, has the advantage of avoiding for parameterization of the distributions appearing in the likelihood-based approach of Section 6 (e.g. the conditional distributions of covariates given past treatment-and covariate history). Instead G-estimation uses a model for the SNFTM and for the conditional distribution of treatment given past treatment-and covariate history. Tests and estimators based on G-estimation have the additional advantage that they can often be calculated with standard software.
Formalization of the problem
We fix a discrete time frame τ 0 = 0 < τ 1 < τ 2 < . . . < τ K throughout the paper, where τ 0 is the time of enrollment in the study (and possibly also initiation of treatment), τ 1 , τ 2 , . . . are the times of the clinic visits, and τ K can be the time of the last clinic visit, or can be chosen past the upper support point of the time-to-AIDS distribution. For simplicity the times of the clinic visits are assumed to be the same for all patients (as long as they are alive).
At each time point τ k we measure a covariate vector L k for each patient, where L 0 may also contain time-independent covariates and information collected before time τ 0 , and we register the treatment given in the interval (τ k , τ k+1 ] in a variable A k , for instance the AZT dosage, assumed constant during the interval. Besides covariates L k and treatments A k , we observe for each person a positive time T , for instance the time from enrollment to the development of clinical AIDS. Thus the data observed on one person is a vector
For time instances τ k > T the values L k and A k may be interpreted to be empty. For simplicity we assume that the variables L k and A k take their values in countable sets, denoted by L k and A k . The total set of observations are a sample of n independent and identically distributed (i.i.d.) observations from the distribution of the random vector (L K , A K , T ).
As is clear from the preceding display we use the overline notation to denote a "cumulative vector". For simplicity of notation, it will be understood that whenever two expressions such as l k and l k−1 occur together, then l k−1 is the initial part of l k .
A "treatment regime" is a prescription for the treatment dosages fixed at the times τ k , where at each time instant the prescribed treatment may depend on the observed covariate history until this time. We make this precise in the following definition.
The value a k = g k (l k ) of the kth coordinate of the treatment regime g at covariate l k is interpreted as the dosage prescribed by treatment regime g in the interval (τ k , τ k+1 ] to a patient with covariate history l k following this regime (up to time τ k ). The treatment at time τ k may depend on the full covariate history
To alleviate notation we may drop the subscripts k or the overline in g k or g k if the value of k is clear from the context. In particular g(l K ) = g(l K ) = g K (l K ) are equivalent notations for the complete treatment history.
We wish to study the effect of treatment using the observed data. Depending on this data not all treatment regimes may be accessible to analysis. We call a treatment regime "evaluable" (relative to the distribution of the data vector (L K , A K , T )) if whenever the regime was followed until some time τ k by some positive fraction of the population, then it is also followed in the interval (τ k , τ k+1 ].
Definition 2.2 (evaluable treatment regimes). A treatment regime g is called evaluable if
Next we introduce counterfactual variables. These will be instrumental both to express the aims of the statistical analysis, and to formulate our assumptions. In our mathematical model the counterfactual variables are ordinary random variables T g , one for each treatment regime g, that are assumed to be defined on the same probability space as the data vector (L K , A K , T ). The variable T g should be thought of as a patient's time to clinical AIDS had she been treated according to treatment regime g. Because in actual fact the patient receives treatmentĀ K (resulting in time to aids T ), the variable T g is "counter to fact". However, it gives a useful notation to express the distribution of interest, and will be related to the observable variables by two assumptions.
Counterfactual variables referring to different subjects are assumed independent (cf. Rubin (1978) ), and hence we can formulate our set-up in terms of the set of random variables (T g , T, L K , A K ) referring to one person. We shall not be interested in the joint distribution of counterfactual variables corresponding to different treatment regimes. We also do not need counterfactual versions of the covariates or treatments.
We describe the aims of the statistical analysis in terms of the counterfactual variables. The G-null hypothesis of no effect of AZT on time-to-AIDS is the hypothesis that
for all treatment regimes g 1 and g 2 .
In Section 6 we derive fully parametric likelihood-based tests of this G-null hypothesis based on a random sample from the distribution of the observables L K , A K , T , and a parametric model for their joint distribution. In Section 7 we develop an alternative, semi-parametric procedure with the same aim. If the G-null hypothesis is rejected, then the next goal is to identify and estimate, for each treatment regime g, the survival curve t → P (T g > t), i.e. the survival curve that would have been observed had a subject followed regime g. Specifically, if our infected subject outside of the study mentioned in the introduction wishes to maximize his expected years of AIDS-free survival, he would follow the regime g that maximized
Inference regarding the distribution of counterfactual variables is referred to as causal inference, as the outcomes T g are interpreted as being the effect of the treatment regime g.
Clearly it is impossible to make inference about the counterfactual survival distributions P (T g > t) based on the observed data unless the variables T g and (L K , A K , T ) are related. The assumed coupling of these variables on a given underlying probability space allows to make the following assumptions relating counterfactual and factual variables.
Assumption 2.3 (consistency). For any treatment regime
Assumption 2.4 (no unmeasured confounding). For any treatment regime g, for any time τ k and for any l k ∈ L k ,
Here the notation X⊥ ⊥Y |Z = z, borrowed from Dawid (1979) , means that the random variabless X and Y are conditionally independent given the event Z = z.
The consistency assumption, Assumption 2.3, couples the true and counterfactual survival times T and T g by merely stating that if until some time τ k a patient is treated exactly as prescribed by regime g, then she would die at some time in the interval (τ k , τ k+1 ] under regime g if and only if she actually died at the same time. This implies in particular that if all patients were treated according to a predetermined treatment regime, then counterfactual and actual survival times coincide. This is the customary situation in clinical trials, but may fail to be the case in an observational study.
The assumption of no unmeasured confounding, Assumption 2.4, can be expected to hold if the observed covariate history L K contains sufficient information, so that at each time τ k the treatment A k can be assumed to depend on the covariate history L k of a patient up till that time and no other relevant information. The assumption would for instance hold if at each time τ k the treatment in the interval (τ k , τ k+1 ] is assigned through randomization within fixed levels of equal covariates L k and earlier treatments.
More specifically, in our AIDS example Assumption 2.4 may be expected to hold if the following information is recorded in L k : all risk factors (i.e. predictors) of regimespecific, counterfactual time-to-AIDS, other than prior AZT-history A k−1 , that are used by physicians and patients to determine the dose
] may be thought of as depending only on external factors unrelated to the patient's prognosis regarding timeto-AIDS, and hence as being independent of T g . For example, since it is known that physicians tend to prescribe AZT to subjects with low CD4-counts and a low CD4-count is an independent predictor of time-to-AIDS, the assumption of no unmeasured confounding would be false if L k does not contain CD4-count history.
It is a basic objective of epidemiologists conducting an observational study to collect data on a sufficient number of covariates to ensure that Assumption 2.4 will be true. In this paper, we assume this objective has been realized, while recognizing that, in practice, this may only approximately be the case.
G-computation
We are interested in the distribution of the counterfactual, and hence unobservable, variables T g , as they indicate the success or failure from applying the treatment regime g. In this section we show that, under Assumptions 2.3 and 2.4, the distribution of T g is identifiable from the distribution of the observed data L K , A K , T for each evaluable treatment regime g. As a consequence, given a random sample from the latter distribution, the distribution of T g is estimable, in principle. In fact, the following G-computation formula gives an explicit expression for P (T g > t), as well as several conditional survival functions, in terms of the distribution of the data
Theorem 3.1 (G-computation-formula). Suppose that Assumptions 2.4 (no unmeasured confounding) and 2.3 (consistency) hold, and that g is an evaluable treatment regime. Then for any t > 0, with p defined by τ p < t ≤ τ p+1 ,
In the preceding theorem we interpret variables indexed by −1 as not present, and events concerning only such variables as being empty. For instance, the conditional probability
All conditional probabilities on the right side concern observable variables. Hence the theorem gives an explicit description of the survival function of the counterfactual variable
It is instructive to evaluate the formula in the simple case that K = 1, when there exists only one treatment A 0 applied in the single interval (0, τ 1 ]. Then the G-computation formula yields, for t > 0,
This shows that in general the distribution of the counterfactual variable T g differs from the distribution of T , which can be written in the form
This difference is not too surprising, because the variable T g refers to the treatment regime g, whereas T relates to the observed outcomes under the actual treatments. Had all patients received treatment g, then the two distributions would coincide. More notable is the difference between the conditional distribution of T given A 0 = a 0 and the distribution of T g for the fixed treatment regime g that assigns all patients to treatment a 0 , i.e. g(l 0 ) = a 0 . These two survival distributions can be written
The conditional distribution of T given A 0 = a 0 is estimable, in principle, by taking only those patients into account who happened to receive treatment a 0 . The outcome distribution of this subset of patients may however be different from the distribution of the counterfactual variable T a 0 , as a result of "selection bias". In the actual world some patients may be assigned other treatments than a 0 , where the assignment A 0 may correlate with the covariate variable L 0 . Therefore, the conditional and unconditional distributions of L 0 given A 0 may differ, and consequently so may the right hand sides of the display. It is the counterfactual survival function t → P (T a 0 > t) that is the relevant one to judge the causal effect of treatment a 0 . Randomization of treatment over patients within fixed levels of the covariate would have made L 0 and A 0 independent, and the difference would disappear. The protocol of a controlled experiment may include such randomization, but in a observational study it cannot be taken for granted. The G-computation formula then shows, under some assumptions, how we can still compute the relevant outcome distributions from the observed data distribution.
We can make further comparisons after deriving a similar representation for conditional probabilities involving the counterfactual variables.
Theorem 3.2 (G-computation-formula).
Under the assumptions of Theorem 2.4, for any k ∈ {0, 1, 2, . . . , K} and any
Again variables indexed by −1 should be read as not being present. Furthermore, a repeated summation of the form l k+1 · · · lp a k,p (l k , l k+1 , . . . , l p ) is considered to be the single term a k,k (l k ) if k = p, whereas the product p k+1 is to be read as 1 in this case. The summation may be restricted to terms whose conditioning events have positive probability.
Again we may evaluate this formula in the simple case of a single treatment interval. Then the formula in the preceding theorem (with k = 0 = p, K = 1) reduces to
The right side is precisely the conditional distribution of the actual survival time for a subject with covariate l 0 following the treatment regime g. Intuitively, the conditional probabilities P T > t|L 0 = l 0 , A 0 = g(l 0 ) are the correct ones for evaluating the quality of treatment g for a subject with covariate value l 0 , and the equality in the preceding display is actually a direct consequence of the Assumptions 2.3 and 2.4 relating the counterfactual and factual survival times. (We may add A 0 = g(l 0 ) in the conditioning event on the left by Assumption 2.4, and next use Assumption 2.3 to see that T g may be replaced by T .) Henceforth, we shall denote the right side of (1) by s l k ,g (t). For k = −1 this reduces to the right side in Theorem 3.1, and we write it as s g (t), interpreting l −1 as empty. Then Theorems 3.1-3.2 can be reformulated as saying that under Assumptions 2.3 (consistency) and 2.4 (no unmeasured confounding), for every evaluable treatment regime g,
and, for every k = 0, 1, . . . , K,
These functions are survival functions of distributions that concentrate on (τ k , ∞). Inspection of the G-computation formula shows that s l k ,g is a (complicated) function of the distribution of the data vector L K , A K , T and depends on this distribution only through the conditional distributions of the covariates and the survival time given the past, given by
and
In particular, the functions s g,l k do not depend on conditional laws of the treatment variables A m given the past.
Proof of Theorems 3.1 and 3.2. We prove Theorems 3.1 and 3.2 by backward induction on k, for fixed t (and hence also fixed p). Formula (1) with k = −1 can be read as the formula given by Theorem 3.1, so we restrict to proving (1). For k = p the left side of (1) is equal to
where in the first equality we can add A p = g p l p in the conditioning event by Assumption 2.4 of no unmeasured confounding, and in the second equality we can replace the event T g > t by the event T > t, because of the Assumption 2.3 of consistency. The induction step is proved by similar arguments. Supposing that (1) holds for k ≤ p, we shall deduce that it also holds for k − 1. We have
The first equality follows by the assumption of no unmeasured confounding, while the second follows by conditioning on the event T g > τ k , where we note that t > τ k , because t > τ p ≥ τ k . By the consistency assumption we can replace the event T g > τ k by the event T > τ k without changing the events or probabilities. Next we can rewrite the second probability as a sum by conditioning on the variable L k , to obtain that the preceding display is equal to
Finally we replace the probability involving the counterfactual variable T g by the right side of (1), which is permitted in view of the induction hypothesis. This yields the right side of (1) for k − 1, and concludes the induction step. 2
Reparameterization
To investigate the effect of a given treatment regime g on survival, it suffices to know the conditional distributions given in (2) and (3). Given these distributions we can compute the counterfactual survival functions by using the G-computation formula, given by Theorem 3.1. Because carrying out this computation may be a formidable task, we may perform the calculation by simulation methods, rather than by analytical calculation. Robins (1986 Robins ( , 1987 Robins ( , 1988 ) provides a Monte Carlo algorithm, called the "Monte Carlo G-computation algorithm", for evaluating the functions s g that satisfactorily resolves potential difficulties with the analytical computation. We refer the reader to these papers for further discussion.
A difficulty is that the distributions in (2) and (3) will typically be unknown and must be estimated from the data. One possibility is to specify models for (2) and (3), for instance logistic or Cox models, and next estimate the unknown parameters from the data. The function s g can then be estimated using the Monte Carlo G-computation algorithm with model derived estimates. Robins (1986 Robins ( , 1987 provides several worked examples of this approach.
This approach has a number of unattractive features. Estimation of the function s g according to the preceding scheme and without confidence intervals, may be feasible, but testing whether treatment affects the outcome is complicated. The models used to specify s g will usually be rough approximations, and the null hypothesis of no treatment effect will be a complex function of all parameters. Standard statistical software may not apply, and in large datasets the null hypothesis will usually be rejected, just because of model misspecification (cf. Robins (1986 Robins ( , 1987 Robins ( , 1988 Robins ( , 1989 ). In this paper we take a different approach, based on a reparameterization of the joint distribution of the observations L K , A K , T using structural nested failure time models (SNFTM).
SNFTMs are models for the causal effect of skipping a "last" treatment dose given the past, thus reverting to the "baseline treatment". To make this precise, suppose that there is a certain baseline treatment regime, which we shall refer to as "no treatment". This could for instance be "zero medication", and consequently we shall let a zero in the sets A k of treatment dosages refer to treatment under the baseline treatment regime.
At any time point τ k a doctor could switch a patient to the baseline regime, at least conceptually, and leave her there. Let a k , 0 be an abbreviation for the treatment regime g = (a 0 , . . . , a k , 0, . . . , 0), i.e. the mth coordinate function of g is given by
Henceforth, we shall always assume that Assumptions 2.3 (consistency) and 2.4 (no unmeasured confounding) are satisfied. Then, by Theorem 3.1, if the treatment regime (a k , 0) is evaluable, the function
(by definition the right side of (1) with g = (a k , 0)) is the conditional survival function of the counterfactual survival time T (ak,0) given the treatment-and covariate history l k , a k−1 up to time τ k , and given that T (ak,0) > τ k . Define "shift-functions" γ by
where the inverse s −1 is the quantile function of the corresponding survival function. The functions γ map percentiles of the distribution of the random variable T ( a k ,0) into those of the distribution of the random variable T ( a k−1 ,0) ,
The functions γ thus measure the effect of skipping the "last" treatment dose a k given the covariate and treatment history (l k , a k−1 ). We assume that the survival functions are continuous and strictly decreasing, so that (4) and (5) give equivalent definitions. If the "last treatment" a k has no effect, then the functions s l k ,(a k−1 ,0) and s l k ,(a k ,0) are identical, and the function γ l k ,a k is the identity function. More generally, the function γ l k ,a k can be seen to measure the effect of the treatment a k given in [τ k , τ k+1 ) on (counterfactual) survival. This is illustrated in Figure 1 .
Figure 1: Illustration of the shift-function γ. In this picture the function s l k ,(a k−1 ,0) lies to the left of the function s l k ,(a k ,0) , indicating that skipping the treatment a k decreases survival for patients with covariate and treatment history (l k , a k−1 ). In this case the function γ l k ,a k is below the identity.
Conversely, if the shift function γ l k ,a k is equal to the identity function, then the distribution of the counterfactual variables T (ak,0) and T (ak−1,0) coincide for patients with past covariate-and treatment history l k and a k−1 . This suggests that, if γ l k ,a k is the identity function for all values of l k , a k and k, then treatment does not affect the outcome of interest: skipping the last treatment does not affect the outcome of interest, next skipping the second-last treatment does not affect the outcome of interest, etcetera.
For a rigorous proof of this conclusion it is necessary that sufficiently many treatment regimes are evaluable, because the functions s l k ,g (defined in terms of the distribution of the observable data by the right side of (1)) are equal to the counterfactual survival distributions only if the treatment regime g is evaluable. For instance, the treatment regime g = a k , 0 need not be evaluable for all a k and hence the distributions of the counterfactual variables T (ak,0) and/or T (ak−1,0) may not be identifiable from the observed data. To overcome this difficulty we assume that the baseline treatment regime 0 is "admissible". A treatment regime is called "admissible" if in every situation there is a positive probability for this regime to be implemented in the next step. As applied to the baseline regime 0, this property takes the form of the following assumption.
Assumption 4.1 (admissible baseline treatment regime). For each k, each l k ∈ L k and each a k−1 ∈ A k−1 ,
Under this assumption the shift functions γ l k ,a k are identifiable for all values of (k, l k , a k ) with P L k = l k , A k = a k , T > τ k > 0, and fully characterize the potential effect of any treatment regime. This is the content of the following theorem, whose proof is deferred to Appendix A. (As shown in Lok (2001, Section 2.12), Assumption 4.1 can be avoided if one allows 0 to be a so-called admissible baseline course of treatment, which may not only depend on past covariate-but also on past treatment history. Some admissible baseline course of treatment, which has a positive probability of occurring after any observed treatment-and covariate history, always exists.) Theorem 4.2 Under Assumptions 2.4 (no unmeasured confounding), 2.3 (consistency) and 4.1 (admissible baseline treatment regime), the distribution of T g is the same under all evaluable treatment regimes g if and only if the shift-function γ l k ,a k is the identity for
It follows that the functions γ l k ,a k characterize the null hypothesis of no treatment effect. Because they also possess an easy interpretation in terms of the effect of a "last blip" of treatment, it is attractive to model these functions rather than the set of conditional distributions in (2) and (3). A structural nested failure time model is a parametrized family of functions used to model the functions γ l k ,a k . Each of the model functions is an increasing function on [τ k , ∞) (that can arise as a quantile-distribution function), with the identity function referring to the absence of the treatment effect.
With the parameter denoted by ψ = (ψ 1 , ψ 2 , ψ 3 ), one example of an SNFTM would be
If ψ = 0, then this function reduces to the identity function, indicating that the parameter value ψ = 0 corresponds to the absence of a treatment effect. For nonzero values of ψ the 
, which corresponds to decreasing survival by skipping the treatment in the interval (τ k , τ k+1 ].
model corresponds to a "change of time scale" depending on present and past treatment (a k , a k−1 ) and present covariate (l k ). The variable L k might for instance be the univariate covariate CD4 lymphocyte count at τ k , and the variable A k the AZT prescription. Then the given model allows for interaction between CD4 lymphocyte count and treatment, and could of course be extended with other factors. Figure 2 shows two typical functions γ following this model.
Mimicking counterfactual outcomes
In the next two sections we present two methods for estimating the parameter ψ in a structural nested failure time model. Theorem 5.1 below is basic for both methods. Consider the following transformation of the observation L K , A K , T , using the "true" shift functions γ (given by (4)):
where p(T ) = max {k : τ k < T }. The application of the function γ L p(T ) ,A p(T ) to T annihilates the effect of the last treatment A p(T ) , and each further application of a shift function annihilates the effect of an earlier treatment. This explains the following theorem, which is proved in Appendix B.
Theorem 5.1 (mimicking counterfactual outcomes). The variable T γ 0 defined in (6) possesses survival function s 0 . Furthermore, for every k ≥ 0,
The variable T γ 0 is a (deterministic) function of the data vector L K , A K , T , through the (unknown) family of shift-functions γ. If the shift functions γ would be known, then we would be able to "mimic" the survival time without treatment by calculating the transformation T γ 0 . By the preceding theorem this variable is distributed according to s 0 and hence under the conditions of Theorem 3.1 possesses the same distribution as T g for g = 0, the null treatment.
Equation (7) shows that the variable T γ 0 also shares the "no unmeasured confounding" property (Assumption 2.4) of counterfactual variables (in a slightly stronger form).
Maximum likelihood estimation
In this section we consider likelihood based inference for the parameter ψ in a given SNFTM. Clearly this requires that we make the parameter ψ visible in the density of the observation L K , A K , T . We first show that this can be achieved using the transformation (6), which will depend on ψ if we use a SNFTM for γ.
Theorem 6.1 (the likelihood rewritten). Suppose that Assumption 4.1 (admissible baseline treatment regime) holds. Suppose moreover that T, L K , A K has a Lebesgue density, and that the function t → s (lk,(ak,0)) (t) is continuously differentiable in t, for all l k , a k
, with strictly negative derivative except for at most finitely many points. Then the joint density of T, L, A can be rewritten as
where τ p < t ≤ τ p+1 and
Proof. Under the conditions of Theorem 6.1,
is a one-to-one mapping. Thus if t γ 0 were continuously differentiable everywhere, then the identity
would be immediate from the change of variables formula. We show that (8) holds under the conditions of Theorem 6.1 too. Next the assertion of the theorem follows by repeated conditioning and using Theorem 5.1. To prove (8) in general, note that the probability space consists of countably many sets of the form L K = l K , A K = a K , so that by countable additivity of measures it suffices to prove (8) on each of these sets that has probability greater than 0. On each of these sets, t γ 0 is one-to-one and continuously differentiable except for at finitely many points: it is the composition of finitely many functions γ l k ,a k and under the assumptions of Theorem 6.1,
exists and is continuous except for at most finitely many t. Thus, from the change of variables formula, equation (8) is true on each set
Regarding the conditions of Theorem 6.1 we note that the baseline treatment regime 0 may not be constant, whence the death rate under 0 may change at the time points τ m . However, it will often be reasonable to assume differentiability of the function s (lk,(ak,0)) (t) on all intervals (τ m , τ m+1 ).
For likelihood inference concerning the parameter ψ of an SNFTM, we shall generally drop the factors
from the likelihood. All other terms involve ψ through T γ 0 and we will need to specify models for these terms in order to proceed, typically involving additional parameters. Given such models we can estimate ψ by the corresponding coordinate of the maximum likelihood estimator obtained by maximizing the likelihood over all parameters. Of course finding this maximizer may be a formidable task.
Since the null hypothesis of no treatment effect is equivalent to the functions γ l k ,a k being equal to the identity function, by Theorem 4.2, this hypothesis can be fully expressed in the parameter ψ. For instance, we could, by convention, construct our SNFTM in such a way that this null hypothesis is equivalent to H 0 : ψ = 0. Then we can obtain a likelihoodbased test for the null hypothesis of no treatment effect using the Wald, score or likelihood ratio test for H 0 : ψ = 0.
G-estimation
The likelihood methods of the preceding section require the specification of models for the conditional laws of the covariates, among others, next to a specification of an SNFTM. In this section we present an alternative approach to testing and estimation of the parameter in a SNFTM, called G-estimation in Robins (1998) . This approach is based on models for the conditional distributions of the treatment variables given in (9). It can be considered a semiparametric approach, where the parametric component refers to the laws (9) and all other laws appearing in Theorem 6.1 form the nonparametric, unspecified component. From a practical perspective modelling the distributions (9) is more attractive than modelling the remaining laws in Theorem 6.1, as it may be expected that doctors have clear ideas, at least qualitatively, about how they reach their decisions about treatment.
The method of G-estimation is based on the conditional independence of the "blippedup" variable T γ 0 defined in (6) and the treatment variable A k given the variables L k and A k−1 , for each k, asserted by Theorem 5.1. Consider first testing the null hypothesis H 0 : γ = γ 0 for a given shift function γ 0 . Theorem 5.1 gives, under the null hypothesis, that, for each k,
This is an assertion about the observed data vector (L K , A K , T ) only. Any test for the validity of (10) is therefore a test for the null hypothesis H 0 : γ = γ 0 . In order to operationalize this idea we adopt for each k a model
for the prediction of treatment given the past, indexed by some parameter θ. Such a model tries to explain the treatment A k by the values of the covariates up to time τ k and the preceding treatment history. Formula (10) implies that, under the null hypothesis, inclusion of the variable T γ 0 0 as an extra explanatory variable is useless for the prediction of A k , if past covariate-and treatment information L k and A k−1 are known. Thus given a term of the form α T γ 0 0 in the prediction model with α a parameter, the true value of α must be equal to 0, because of (10). It follows that we can test the null hypothesis H 0 : γ = γ 0 by adding a term αT γ 0 0 anyway, and next test the null hypothesis H 0 : α = 0 in the model indexed by the overall parameter (θ, α). Depending on the chosen types of model such a test, for instance a Wald, score or the likelihood ratio test, can be performed by standard statistical software.
This procedure is particularly simple for testing the null hypothesis of no treatment effect. In view of Theorem 4.2, this is equivalent to testing whether the function γ is equal to the identity function, i.e. we take γ 0 in the preceding equal to the identity function. In this case the variable T γ 0 0 is equal to T , and hence the G-estimation procedure reduces to testing the null hypothesis H 0 : α = 0 in a regression model that tries to explain the variable A k by the variables L k , A k−1 and αT . The null hypothesis of no treatment effect can be tested in this way without specifying a model for the shift function γ.
For a specific example, suppose that the treatment variables A k are binary-valued. Then a logistic regression model is a standard choice for modelling the probabilities (9). We might add the variable αT γ 0 to a logistic regression model to form the model
, for given, known functions f k and g k , and unknown parameters θ and α. A test for the null hypothesis H 0 : α = 0 can be carried out by standard software for logistic regression.
Given an SNFTM ψ → γ ψ for the shift functions γ, indexed by a parameter ψ, we can extend the preceding testing methods to full inference on the parameter ψ. First, we can obtain confidence regions for ψ by inverting the tests for the null hypotheses H 0 : γ = γ ψ in the usual way: the value ψ belongs to the confidence region if the corresponding null hypothesis H 0 is not rejected.
A natural estimator of ψ would be the center of a confidence set, or, alternatively, a value of ψ for which T γ ψ 0 contributes the least to the prediction model for treatment given the past. That is, the ψ for which the fitted model for
does not include the variable T If we use a logistic regression model, then the estimatorsθ andα can be obtained with standard software, for each given value of ψ. The estimatorψ can next be found by a grid search method. Alternatively, we can implement a direct numerical method for estimating ψ.
The procedures just outlined may appear a bit unusual, in view of their indirect nature. However, in most cases they can also be interpreted in a standard way. For instance, the procedure for estimating α for given ψ will often be equivalent to solvingα =α (ψ) from an estimating equation of the type
Thenψ satisfyingα ψ = 0 will satisfy the estimating equation
Because α(ψ 0 ) = 0 for the true value ψ 0 of ψ, the true value of ψ is a solution to the equation
In other words,ψ will be the solution of an unbiased estimating equation, whence the (asymptotic) properties ofψ can be ascertained with the usual theory for M-estimators (e.g. Van der Vaart (1998) ). For instance, we may expect the sequence √ n ψ − ψ to be asymptotically (as n → ∞) normal with mean zero and variance Lok (1991) has studied the validity of these results, and has thus justified the preceding procedures.
Summary and extensions
We have shown that the AZT treatment regime-specific, counterfactual AIDS-free survival curves P (T g > t) are identified for all evaluable treatment regimes g if our maintained assumption of no unmeasured confounding, Assumption 2.4, is met. This assumption will hold if the investigator has succeeded in recording in l k data on all covariates that, conditional on past AZT history a k−1 , predict both the AZT dosage rate a k in (τ k , τ k+1 ] and the random variables T g representing time to AIDS had, contrary to fact, all subjects followed an AZT treatment history consistent with regime g.
Further, we have shown that, under the assumption of no unmeasured confounding, Assumption 2.4, the shift functions γ of an SNFTM are the identity function if and only if the G-null hypothesis of no causal effect of AZT on time to AIDS is true. We have expressed the likelihood of the observable random variables T, L K , A K in terms of the transformed random variables T γ 0 , L K , A K . We then developed parametric likelihood based tests of the hypothesis γ = id by specifying fully parametric models for the joint distribution of T, L K , A K in terms of the transformed random variables
Even in the absence of censoring or missing data, a major limitation of the fully parametric likelihood-based tests of the null hypothesis γ = id from Section 6 is that misspecification of the parametric models for the distribution of L k given L k−1 , A k−1 and T γ 0 , or for the distribution of T 0 , can cause the true α-level of the test to deviate from the nominal α-level. This limitation raised the question of whether it is possible to construct α-level tests of the null hypothesis γ = id and of more general hypotheses concerning γ, which are asymptotically distribution-free. A closely related question is whether there exist n 1/2 -consistent asymptotically normal estimators of the parameter ψ of a correctly specified structural nested failure time model if the joint distribution of the observables L K , A K , T is otherwise unspecified, i.e. if the distribution of L k given L k−1 , A k−1 and T γ 0 and the distribution of the variable T 0 are left completely unspecified. In Section 7 we showed that one only needs to specify a parametric model for the shift function γ, which models the causal effect of one treatment dosage given the past, and a parametric model for the distribution of actual treatment dosage given past treatment-and covariate history. Doctors will usually have clear ideas about this latter distribution of treatment decisions. Moreover, the doctors' interest will often be in the causal effect of one treatment dosage given the past.
If the null hypothesis of no treatment effect has been rejected and the parameter ψ of the shift function γ has been estimated, one might wish to estimate the survival distribution t → P T g > t of the outcome under specific treatment regimes g in a way consistent with the estimatorψ. This can be done by estimating the distribution of T 0 (e.g. by the empirical distribution of T (i = 1, 2, . . .) from the distribution of T g could then be generated by using these estimated distributions: first draw T 0 from the distribution of
This variable will be generated from the desired distribution. Extensions of the results of this paper that allow for censoring and missing data are discussed in Robins (1988 Robins ( , 1992 Robins ( , 1993 Robins ( , 1998 , and Robins et al (1992) . The extension of G-tests and estimators to continuous L k and A k are discussed in Robins (1992 Robins ( , 1993 , Robins et al. (1992) , and Gill and Robins (2001) . Robins (1998) and Lok (2001) show that the results in this paper can be extended to allow for jumps in the treatment-and covariate processes in continuous time.
A Alternative formulation of the null hypothesis
In this appendix we prove Theorem 4.2 through two lemmas. The first lemma shows that if all functions γ are equal to the identity function, then all survival curves P (T g > t) for evaluable treatment regimes are the same. The second lemma shows the reverse.
Lemma A.1 Suppose that Assumptions 2.4 (no unmeasured confounding), 2.3 (consistency) and 4.1 (admissible baseline treatment regime) hold. If
for evaluable treatment regimes g are the same.
Proof. We show that for all evaluable treatment regimes g and all l k with
For k = −1 this should be read as s g (t) = s 0 (t), which implies Lemma A.1. We prove (12) by backward induction on k, for t fixed. With τ p the last clinic visit time strictly before t, we start with k = p and end with k = 0. The statement for k = −1 follows from the statement for k = 0 by summation over l 0 .
Basis: For k = p, by the definition of s as the right side of (1),
by another application of the definition of s. The right side is equal to s lp,(g p−1 (lp−1),0) (t)
by the assumption that the function γ l p ,ap with a p = g p (l p ), is the identity function is the identity.
Induction step: we suppose that (12) is true for k ≥ 1 and establish (12) for k − 1. By straightforward algebra using the definition of s l k−1 ,g ,
Here we can replace s l k ,g using the induction hypothesis, giving that the preceding display is equal to
where we use the definition of s in the first equality, and the assumption that γ l k−1 ,a k−1 , for a k−1 = g k−1 (l k−1 ), is the identity function in the second. 2
Lemma A.2 Suppose that Assumptions 2.4 (no unmeasured confounding), 2.3 (consistency) and 4.1 (admissible baseline treatment regime) hold. If the survival curves P (T g > t) are the same for all evaluable treatment regimes g, then the shift function γ l k ,a k is the identity for all k, l k ∈ L k and a k ∈ A k with P L k = l k , A k = a k , T > τ k > 0.
Proof. Let fixed l k , a k with P L k = l k , A k = a k , T > τ k > 0 be given. To prove that γ l k ,a k is the identity we need to show that, for all t > τ k , s l k ,(a k ,0) (t) = s l k ,(a k−1 ,0) (t).
Define a treatment regime g 1 by the coordinate functions g 1 m l m = a m ifl m is the initial part of l k , and by g 1 m l m = 0 otherwise. Define a second treatment regime g 2 by and g 2 = g 1 k−1 , 0 . Because of Assumption 4.1 and because P L k = l k , A k = a k , T > τ k > 0, the treatment regimes g 1 and g 2 are evaluable. Thus, by assumption, we have that P (T g 1 > t) = P (T g 2 > t), and these probabilities are given by the G-computation formula, given in Theorem 3.1. For the first regime this formula can be written in the form A similar expression holds for the treatment regime g 2 . Because the regimes g 1 and g 2 are constructed to be the same up to time τ k−1 , only the second terms of the summs differs between these two expressions. Even there, the product preceding s l k ,g 1 (t) and s l k ,g 2 (t) is the same for g 1 and g 2 . Moreover, this factor is strictly positive, since P L k = l k , A k = a k , T > τ k > 0 by assumption. The equality of P (T g 1 > t) and P (T g 2 > t) therefore implies the equality of s l k ,g 1 (t) and s l k ,g 2 (t). By construction of g 1 and g 2 , equation (13) and hence Lemma A.2 follow. 2
B Mimicking counterfactual outcomes
For t > 0 define p(t) by τ p(t) < t ≤ τ p(t)+1 , i.e. τ p(t) is the last clinic visit time strictly before t. For k ≥ 0 with k ≤ p(T ) we define a random variable by
For k > p(T ) we interprete the (empty) composition of transformations on the right as the identity and define T γ k = T . In this appendix we prove the following theorem, which generalizes the first part of Theorem 5.1. This theorem implies the second part, since T Theorem B.1 For t > τ k and every l k , a k with P L k = l k , A k = a k , T > τ k > 0,
Proof. We use backward induction on k, starting with k = K and ending with k = 0.
= s l K ,(a K−1 ,0) (t).
Here the first equality is immediate from the definition of T γ K , the second follows by the strict monotonicity of the functions γ, the third by definition of s and the last by definition of γ.
Induction step: we show that if the theorem is true for k + 1, then it is also true for k. Just as for k = K,
Now we distinguish two possibilities: γ −1 l k ,a k (t) ≤ τ k+1 and γ −1 l k ,a k (t) > τ k+1 . In the first case, the right side of the preceding display is equal to
where the first equality holds because for s ∈ (τ k , τ k+1 ] we have that T γ k+1 > s = {T > s} by the construction of T γ k+1 , and the last equality holds by the definition of γ. In the second possibility, i.e. if γ
P L k=1 = l k+1 |L k = l k , A k = a k , T > τ k+1 s l k+1 ,(a k−1 ,0) (t) = s l k ,(a k−1 ,0) (t), where in the first step we condition on T γ k+1 > τ k+1 , in the second we use that T γ k+1 > τ k+1 = {T > τ k+1 } and we condition on L k+1 , the fourth is the induction step, the fifth follows from the definition of γ and the last from the definition of s l k ,(a k−1 ,0) . 2
